Month: December 2025

Outcomes Favor Below-Knee Over Above-Knee Amputation in Patients With Nontraumatic Lower Extremity Wounds



Patient-Reported Outcomes Favor Below-Knee Over Above-Knee Amputation in Patients With Nontraumatic Lower Extremity Wounds

Summary: Cross-sectional study (n=96 nontraumatic chronic LE wound patients post-amputation: 74 BKA, 22 AKA) compared PROMs. BKA showed lower psychological distress (SRQ-20 3.1 vs 5.6, p=0.002), lower pain (PROMIS-3a 48.2 vs 58.9, p=0.001), higher function (LEFS 47.4 vs 33.9, p=0.003). BKA preserved knee, enabled better prosthesis/ambulation; higher TMR rates. Prior psychiatric diagnoses higher in AKA but not significant covariate. Supports prioritizing BKA when feasible for QoL/mobility.

Key Highlights:

  • Distress: BKA lower (p=0.002); pain lower (p=0.001).
  • Function: LEFS higher BKA (p=0.003); knee preservation key.
  • TMR: 66% BKA vs 18% AKA.
  • Limitations: Cross-sectional, small AKA sample.
  • Authors: Steven Tohmasi et al.

Read full research

Keywords: BKA, AKA, PROs, QoL, amputation, Steven Tohmasi

HMP Global’s Wounds Launches CTP News Desk: Central Hub for Real-Time Updates on ….



HMP Global’s Wounds Launches CTP News Desk: Central Hub for Real-Time Updates on Cellular and Tissue-Based Products

Summary: HMP Global’s *Wounds* journal launched the CTP News Desk, a digital hub curating real-time developments in cellular/tissue-based products (CTPs): reimbursement, coverage, legislation, market impact. Provides expert analysis to help clinicians navigate rapid changes affecting patient access. Centralized, credible source for policy updates and interpretations.

Key Highlights:

  • Content: Reimbursement/coverage news, expert commentary, legislative insights.
  • Benefits: Clarity on changes, informed decisions, improved access.
  • Access: Free via Wounds site; ongoing updates.

Visit CTP News Desk

Keywords: CTP News Desk, cellular tissue products, reimbursement, policy, HMP Global

From Screening to Full Risk Assessment in Pressure Injury Prevention



From Screening to Full Risk Assessment in Pressure Injury Prevention

Summary: Article outlines 2019 International Guideline’s two-step PI prevention: screening (quick, on admission for mobility/friction/Stage 1) then full assessment if risk not ruled out (scales like Braden + clinical judgment, head-to-toe skin check). PURPOSE-T tool supports both; high-risk settings may skip screening. Emphasizes modifiable factors, interprofessional input, reassessment; examples from Australia/Germany policies.

Key Highlights:

  • Screening: Dichotomous (risk/no risk); fast, no full skin exam.
  • Full: Scales + judgment; factors like perfusion/nutrition.
  • Tools: Braden/Norton/Waterlow; PURPOSE-T qualitative.
  • Best Practices: Structured, population-specific, ongoing evaluation.

Read full article

Keywords: PI risk assessment, screening, full assessment, PURPOSE-T, prevention

Observational Study of Venous Leg Ulcer Treated With Native Collagen-Alginate Dressing



Observational Study of Venous Leg Ulcer Treated With Native Collagen-Alginate Dressing and Impact on Wound-Related Quality of Life

Summary: Observational study (n=60 non-healing VLUs, 1.5-24 months) used native collagen-alginate (Cutimed Epiona) + SOC/compression. At 4 weeks: area ↓32% (17.8 to 11.4 cm², p<0.0001); 4 complete closures; pain ↓56% (VAS 3.9 to 1.7, p<0.0001); analgesic use ↓47%; QoL improved (Wound-QoL total/sub-scores p<0.0001). Periwound skin/exudate improved; rated 'very good/good' by all HCPs. Safe adjunct accelerating healing/QoL in VLUs.

Key Highlights:

  • Area: ↓32% mean; 4 full closures.
  • Pain: VAS ↓56%; analgesics ↓ from 61% to 33%.
  • QoL: Significant ↓ Wound-QoL scores (body/wellbeing/everyday).
  • Safety: 8 moderate AEs (unlikely related).

Read full study

Keywords: collagen alginate, VLU, healing, QoL, observational

HMP Global’s SAWC Announces 2026 Partnership with NPIAP



HMP Global’s SAWC Announces 2026 Partnership with NPIAP

Summary: HMP Global’s Symposium on Advanced Wound Care (SAWC) Spring 2026 partners with National Pressure Injury Advisory Panel (NPIAP) for expanded two-day educational track on pressure injury prevention/management. Event: April 8-12, Charlotte, NC. Includes registration incentives for SAWC/NPIAP conferences; aims to advance evidence-based PI care amid rising incidence.

Key Highlights:

  • Track: Two-day PI focus with NPIAP guidelines.
  • Dates: April 8-12, 2026; Charlotte Convention Center.
  • Goals: Multidisciplinary education on prevention/outcomes.
  • Incentives: Cross-registration benefits.

Read press release

Keywords: SAWC 2026, NPIAP, pressure injury, partnership, Charlotte

Simple and Effective Approach for Wound-Bed Preparation by Topical Citric Acid Application



Simple and Effective Approach for Wound-Bed Preparation by Topical Citric Acid Application

Summary: Empirical study (n=24 chronic wounds ≥10 cm, unresponsive >3 weeks) used 2% citric acid ointment daily post-saline irrigation. All achieved healthy granulation in 3-20 applications; controlled MDR infections (S. aureus 37.5%, P. aeruginosa 25%) without systemic antibiotics (unless systemic signs). No toxicity; acidic milieu unfavorable to microbes while promoting healing. Superior to conventional antiseptics (betadine/H2O2) in efficacy/cost for large raw areas.

Key Highlights:

  • Wounds: Large raw areas; MDR isolates dominant.
  • Outcomes: Granulation in all; ready for grafting/secondary healing.
  • Safety: No local/systemic toxicity.
  • Vs Standard: Faster preparation, economical, non-toxic to cells.

Read full study

Keywords: citric acid, wound bed preparation, chronic wounds, MDR, granulation

Vohra Wound Physicians Fraud/Overbilling



Vohra Wound Physicians Fraud/Overbilling

Summary: Caroline Fife discusses the DOJ’s $45M settlement with Vohra Wound Physicians for alleged Medicare fraud: unnecessary excisional debridements, upcoding routine care, non-billable E/M, and EHR defaults to high-reimbursement codes. Highlights physician pressure via incentives/training and software manipulation. Views as wake-up call for wound care billing integrity; anticipates increased audits on debridement claims in SNFs. Notes inconsistent terminology (excisional vs selective) contributes to confusion.

Key Highlights:

  • Allegations: EHR auto-upcoding, quotas, false documentation.
  • Settlement: $45M + 5-year CIA.
  • Implications: Scrutiny on SNF wound billing; education gaps.
  • Perspective: “Stunning” case of systemic overutilization.

Read commentary

Keywords: Vohra, fraud, overbilling, debridement, Caroline Fife

Optimizing the Wound Bed for Better Outcomes



Healing Starts Here: Optimizing the Wound Bed for Better Outcomes

Summary: This WoundSource webinar focuses on wound bed preparation as foundational for healing chronic wounds (DFUs, VLUs, PIs). Key topics: TIME framework (Tissue management, Infection/Inflammation, Moisture balance, Edge advancement); debridement methods (autolytic, enzymatic, sharp); exudate control (absorptives, NPWT); biofilm disruption (antiseptics, surfactants). Speakers discuss evidence-based products and techniques to convert stalled wounds to healing trajectory, with case examples showing 30-50% faster closure via optimized preparation.

Key Highlights:

  • TIME Principles: Core for chronic wound conversion.
  • Debridement: Sharp preferred for speed; enzymatic for maintenance.
  • Infection: Antiseptics over antibiotics for biofilm.
  • Moisture: Balance to avoid maceration/dryness.
  • Outcomes: Optimized prep ↑ healing 30-50%.

Register/watch webinar

Keywords: wound bed preparation, TIME, debridement, biofilm, chronic wounds

Use of Oral Antibiotics for Diabetic Foot Osteomyelitis



Use of Oral Antibiotics for Diabetic Foot Osteomyelitis: A Systematic Review

Summary: This PRISMA-guided systematic review (MEDLINE/EMBASE to July 2024) analyzed 26 studies (4 RCTs, 22 observational, n=972 DFO patients) on oral antibiotics (monotherapy 73.8%, step-down 26.2%). Mean duration 95 days; follow-up 12 months. Complete resolution: 75% monotherapy, 56% step-down; overall 70%. Recurrence low (5%). AEs in 24% (mostly mild GI/liver); no deaths. Oral therapy comparable to IV for efficacy, with advantages in cost/accessibility; supports outpatient/low-resource use with stewardship.

Key Highlights:

  • Efficacy: 70% complete/partial resolution; 22% no resolution/amputation.
  • Safety: 44 AEs (mild); 2 discontinuations.
  • Classes: Penicillins 44%, fluoroquinolones 17%.
  • Limitations: Heterogeneity, few RCTs, reporting bias.
  • Authors: Siddhartha Sood, Ryan Geng, Jihad Waked, Asfandyar Mufti et al.

Read full review

Keywords: oral antibiotics, DFO, osteomyelitis, outpatient, stewardship, Siddhartha Sood, Ryan Geng, R Gary Sibbald

Nonhealing Wound Debridement Using a Finger-Mounted Debridement Tool



Nonhealing Wound Debridement Using a Finger-Mounted Debridement Tool

Summary: Prospective single-arm pilot (n=11 patients, 12 chronic wounds: venous, surgical, PI, DFU) evaluated DigiTouch finger-mounted debridement tool (Medline). Procedure time 43s; effective slough/biofilm/fibrin removal; wounds showed bleeding surface post-debridement. Clinicians rated ease/access 5/5 (superior to traditional); patients low pain (67% 0/10), preferred tool (89%). No AEs; minimal bleeding. Demonstrates feasibility for precise, patient-friendly debridement in hard-to-reach areas.

Key Highlights:

  • Wounds: Mean area 9 cm²; 92% no/minimal bleeding post.
  • Efficacy: Slough (8), biofilm (5), fibrin (7) removed.
  • Satisfaction: Clinicians 5/5 ease; patients 78% faster/89% easier.
  • Safety: No excessive bleeding/infection.
  • Author: Elvis Castillo-Garcia.

Read full pilot

Keywords: finger mounted debridement, DigiTouch, chronic wounds, pilot study, patient satisfaction, Elvis Castillo-Garcia

Predictive Model of Chronic Wounds Identifies Risk Factors for Amputation and Death



Predictive Model of Chronic Wounds Identifies Risk Factors for Amputation and Death

Summary: Multistate model from Regenstrief Chronic Wound Registry/INPC (n=52,916 Indiana lower-extremity chronic wound patients, 2011-2021) predicts progression to amputation/death. Key: DFUs ↑ minor amputation risk; venous ulcers ↓ amputation/death; pressure ulcers ↑ death but ↓ minor amputation; osteomyelitis ↑ amputation but ↓ death pre-major; sepsis ↑ death pre-major. 3-year mortality: >10% post-diagnosis, ~13% post-minor, 19% post-major. Model supports proactive decisions; registry expansion planned for ML on notes/socioeconomics.

Key Highlights:

  • Population: 52,916 patients; lower-extremity chronic wounds.
  • Risks: DFU ↑ minor amp; venous ↓ overall; pressure ↑ death; sepsis/osteomyelitis modifiers.
  • Mortality: 3-year >10% diagnosis, 13% minor amp, 19% major amp.
  • Quotes: Schleyer/Choi on real-world data for earlier intervention.
  • Source: Annals of Surgery (DOI: 10.1097/sla.0000000000006761).

Read full news

Keywords: chronic wounds, amputation risk, mortality, multistate model, Regenstrief

The “Comfort Paradox”: Why Feeling Good Might Be Bad for the Diabetic Foot



The “Comfort Paradox”: Why Feeling Good Might Be Bad for the Diabetic Foot

Summary: This blog post discusses the “Comfort Paradox” in diabetic neuropathy: patients select shoes based on comfort/fit, but loss of protective sensation means they cannot detect harmful friction/pressure. Up to 82% wear improper footwear (33-43% too short, 46% too narrow), increasing DFU risk. Cites Carral-Sota et al. review emphasizing therapeutic shoes reduce ulcers/amputations. Recommends “Goldilocks” fit (1-2 cm toe clearance), rigid/rocker soles for offloading over soft cushioning; avoid sandals. Structured shoes > comfort priority for prevention.

Key Highlights:

  • Paradox: Comfort perception unreliable without sensation.
  • Stats: 33-82% improper fit; ↑ DFU risk.
  • Recommendations: Rigid/rocker soles, extra depth, professional fitting.
  • Cited: Carral-Sota review (J Clin Med 2025).
  • Contributors: ALPSlimb, Keck School USC; #ActAgainstAmputation.

Read full post

Keywords: comfort paradox, neuropathy, diabetic footwear, offloading, DFU prevention

Challenges in Cadaveric Skin Graft Survival in Organ Transplant Recipients on …



Challenges in Cadaveric Skin Graft Survival in Organ Transplant Recipients on Immunosuppressive Regimens: A Case Report

Summary: Case report of two liver-kidney transplant recipients on chronic immunosuppression (tacrolimus/mycophenolate ± prednisone) who received cryopreserved cadaveric skin allografts (PureSkin) for lower-extremity wounds. Initial adherence at 2 weeks, but grafts disintegrated by 4-8 weeks despite therapy. Wounds granulated well but did not integrate grafts; patients declined STSG, opting for local care (one healed secondary intention, one died from pulmonary disease). Highlights unpredictable long-term allograft survival in immunosuppressed patients, with initial benefits but eventual rejection; suggests exploring local immunosuppression or alternatives like cellular matrices.

Key Highlights:

  • Patient 1: 59M, trauma hematoma/necrosis; graft failed 4 weeks; healed secondary.
  • Patient 2: 62M, necrotizing infection; graft failed 8 weeks; died pulmonary.
  • Challenges: Immunosuppression prolonged initial survival but not integration.
  • Lessons: Extended follow-up needed; consider alternatives in high-risk patients.
  • Authors: Steven Tohmasi, Carolyn Tsung, Ariana Naaseh, Jennifer Yu, John P. Kirby, Lindsay M. Kranker.

Read full case report

Keywords: cadaveric graft, immunosuppression, transplant, rejection, lower extremity, Steven Tohmasi, John P Kirby

Multicenter Hybrid Platform Trial Evaluating Amniotic Tissue Grafts in Chronic Wounds



Multicenter Hybrid Platform Trial Evaluating Amniotic Tissue Grafts in Chronic Wounds: A Real-World Evidence Protocol for Diabetic Foot and Venous Leg Ulcers

Summary: This protocol describes a multicenter hybrid platform trial using real-world evidence to evaluate amniotic tissue grafts for hard-to-heal DFUs and VLUs. Umbrella design with two parallel prospective cohorts (DFU/VLU), each randomized 1:1 to trilayer amnion graft (Tri-Membrane Wrap) or single-layer (Membrane Wrap-Lite) + SOC vs a shared retrospective matched SOC control (coarsened exact matching from US Wound Registry). Inclusion: adults ≥18, ulcers ≥4 weeks/2-24 cm²/<50% reduction prior 4 weeks. Sample: 55/group (165 total). Primary: complete wound closure at 12 weeks. Secondary: PAR at 4/8/12 weeks, time to closure. Prospective arms include WOUND-Q QoL/pain; safety monitoring. Aims to provide generalizable insights on amniotic grafts' role in chronic wound care.

Key Highlights:

  • Design: Hybrid (prospective randomized + retrospective matched control).
  • Products: Tri-Membrane Wrap (trilayer) vs Membrane Wrap-Lite (single-layer) from BioLab Holdings.
  • Power: 80% for 30% healing difference (α=0.05).
  • Patient-Centered: QoL/pain scores in prospective arms.
  • Authors: Windy Cole, Marissa Carter, Caroline Fife, Marissa Docter.

Read full protocol

Keywords: amniotic grafts, DFU, VLU, hybrid trial, real world evidence, Windy Cole, Caroline Fife

Surgical Approaches to Diabetic Foot Ulcers: An Algorithm for Applying the Reconstructive Ladder



Surgical Approaches to Diabetic Foot Ulcers: An Algorithm for Applying the Reconstructive Ladder

Summary: Narrative review proposes algorithmic surgical DFU management using reconstructive ladder: preoperative optimization (glycemic/vascular/infection), serial debridement, adjuncts (NPWT/DRTs), definitive closure escalating from secondary intention/primary to grafts/flaps. Multidisciplinary orthoplastic approach reduces amputations 62-82%; emphasizes Wagner/Texas/SINBAD classification, offloading, education for durable coverage/ambulation.

Key Highlights:

  • Optimization: HbA1c control, vascular eval, infection eradication.
  • Debridement: Early radical to restart healing.
  • Adjuncts: NPWT for granulation, DRTs as scaffolds.
  • Ladder: Secondary → primary → STSG → local flaps → pedicled flaps.
  • Outcomes: MDT ↓ amputations; flaps for exposed structures.

Read full open-access review

Keywords: DFU surgical, reconstructive ladder, limb salvage, flaps, orthoplastic, Subhas Gupta, Janine Myint

Biomarkers in Wound Healing



Biomarkers in Wound Healing

Summary: This chapter synthesizes biomarkers across wound healing phases: hemostasis (PDGF, thrombin), inflammation (IL-1β, TNF-α, MMPs), proliferation (VEGF, EGF, TGF-β), remodeling (TIMPs, collagen I). In chronic wounds/DFUs, persistent inflammation (↑ cytokines), proteolytic imbalance (↑ MMPs), growth factor deficits, and biofilms stall repair. Biomarkers enable differentiation acute/chronic, therapy monitoring, outcome prediction, and personalized interventions (e.g., protease modulators for high MMPs). Advances in detection (POC tests, proteomics) shift wound care to predictive precision.

Key Highlights:

  • Phases: Hemostasis (PDGF), inflammation (IL-6/TNF-α/CRP), proliferation (VEGF/PDGF), remodeling (TIMPs/collagen I).
  • Chronic Disruptions: ↑ cytokines/MMPs, ↓ growth factors, biofilms → delayed healing.
  • Applications: Monitor efficacy (MMP ↓ post-debridement), predict risk (high mediators), guide infection surveillance.
  • Future: Metabolic profiling/proteomics for novel targets; POC for real-time decisions.
  • Authors: Tintswalo N. Mgwenya, Phumlane S. Mdluli

Read full open-access chapter

Keywords: wound biomarkers, chronic wounds, DFU, inflammation, precision, Tintswalo N Mgwenya, Phumlane S Mdluli

A Machine-Learning-Based Clinical Decision Model for Predicting Amputation Risk



A Machine-Learning-Based Clinical Decision Model for Predicting Amputation Risk in Patients with Diabetic Foot Ulcers

Summary: Retrospective study (n=149 hospitalized DFU patients) developed a support vector machine (SVM) model to predict lower-limb amputation risk using CRP and Wagner grade as key predictors. Model achieved AUC 0.89, accuracy 82.4%, sensitivity 79.6%, specificity 86.5%; outperformed LDA/KNN. Decision curve analysis showed net benefit at 30% threshold. Provides quantitative tool for early intervention, individualized strategies, and multidisciplinary care in high-risk DFUs.

Key Highlights:

  • Predictors: CRP and Wagner grade (independent via LASSO, p<0.05).
  • Performance: AUC 0.89; moderate calibration (p=0.012); net benefit 0.351.
  • Validation: 5-fold cross-validation; 82.4% correct classification.
  • Implications: Identifies high-risk patients for aggressive management; external validation needed.
  • Authors: Lei Gao, Zixuan Liu, Siyang Han et al.

Read full open-access article

Keywords: DFU amputation, machine learning, SVM, CRP, Wagner grade, Lei Gao, Zixuan Liu, Siyang Han

Surgical Approaches to Diabetic Foot Ulcers



Surgical Approaches to Diabetic Foot Ulcers: An Algorithm for Applying the Reconstructive Ladder

Summary: Narrative review proposes algorithmic surgical management of DFUs using the reconstructive ladder: preoperative optimization (glycemic/vascular/infection control), serial debridement, adjuncts (NPWT, templates), then escalation from secondary intention/primary closure to grafts/flaps based on size/depth/response. Multidisciplinary orthoplastic approach reduces amputations 62-82%; emphasizes staging (Wagner/Texas/SINBAD), offloading, and patient education for durable weight-bearing coverage.

Key Highlights:

  • Ladder: Secondary → primary → STSG/FTSG → local flaps → regional pedicled flaps.
  • Optimization: HbA1c control, vascular eval, infection eradication.
  • Adjuncts: NPWT ↑ granulation; templates for grafts.
  • Outcomes: MDT ↓ amputations; flaps for exposed tendon/bone.
  • Authors: Subhas Gupta, Janine Myint

Read full open-access article

Keywords: DFU surgical, reconstructive ladder, limb salvage, flaps, orthoplastic, Subhas Gupta, Janine Myint

A Bioabsorbable Body-Coupling-Electrotherapy Suture


Read full open-access article

Keywords: electrotherapy suture, bioabsorbable, healing efficiency, infection reduction, body coupled, Zhouquan Sun, Yuefan Jin, Hui Su

Biocompatible Stimuli-Sensitive Natural Hydrogels


Read open-access review

Keywords: natural hydrogels, stimuli sensitive, wound healing, antimicrobial, clinical trials

Why Ambient AI Is the Missing Link in Clinical Trial Data Integrity



The Site Perspective: Why Ambient AI Is the Missing Link in Clinical Trial Data Integrity

Summary: From the investigator viewpoint, ambient AI acts as a consent-based medical scribe in clinical trials, drafting notes from natural conversations to capture nuanced wound details (size, exudate, offloading compliance) in a DFU skin substitute study. It separates chit-chat from clinical data, flags omissions (e.g., side effects), and allows review/sign-off, reducing manual entry errors and queries. Benefits: richer source data, fewer missing AEs/symptoms, focus on verification over entry; supports compliance in complex wound assessments.

Key Highlights:

  • Application: DFU trial for skin substitute; captures fleeting details prone to loss.
  • Process: Listens with consent, drafts templated notes, investigator validates.
  • Benefits: ↓ omissions (99% capture), fewer queries, natural patient interaction.
  • Integrity: Shifts from data entry to verification; flags missing info.
  • Perspective: Site-level view on ambient AI as “missing link” for trial quality.

Read full article

Keywords: ambient AI, clinical trials, DFU, data integrity, skin substitute

Incidence, Hospitalization and Mortality and Their Changes Over Time



Incidence, Hospitalization and Mortality and Their Changes Over Time in People with a First Ever Diabetic Foot Ulcer

Summary: Analysis of UK CPRD GOLD database (2007-2017, n=129,624 diabetes patients) shows declining trends in first DFU outcomes for type 2 diabetes: incidence rate ratio per year 0.97, hospitalization OR 0.89, 1-year mortality OR 0.94. No significant changes for type 1. Mean first DFU incidence 2.5/1000 person-years (type 2) vs 1.6 (type 1). Improvements attributed to better primary care prevention/management of initial ulcers.

Key Highlights:

  • Incidence: Type 2 ↓ (IRR 0.97/year); type 1 stable.
  • Hospitalization: Type 2 average 8.2% ↓ (OR 0.89).
  • Mortality: Type 2 11.7% 1-year risk ↓ (OR 0.94).
  • Population: UK primary care; insulin/non-insulin prescriptions.
  • Implications: Positive shift in type 2 DFU prevention/outcomes.

Read full blog post

Keywords: DFU incidence, UK trends, hospitalization, mortality, primary care

Biomedical Aerogels in Wound Healing


Read full open-access review

Keywords: aerogels, wound healing, DFUs, antimicrobial, angiogenesis, Yukun Liu, Kang Wang, Fangli Gao

WoundTalk: Virtual Platform for Wound Care Professionals



WoundTalk: Virtual Platform for Wound Care Professionals

Summary: WoundTalk (woundtalk.lerexpo.com) is a virtual platform by Lower Extremity Review Expo for wound care pros (physicians, nurses, podiatrists) to access accreditation, agendas, and speaker sessions. Upcoming: Jan 8, 2026, “Giving Lymphedema The Squeeze: All Things Compression” (6pm ET) with Dr. Loan Lam (DPM), Cam Ayala (lymphedema advocate), and Windy Cole (DPM, CWSP). Facilitates knowledge sharing on DFUs (offloading, biologics), PIs (staging, bundles), and compression via live/virtual events, CE credits, and networking. Free registration; hybrid format.

Key Highlights:

  • Purpose: Education/networking for lower extremity wounds.
  • Features: Accreditation, agendas, speaker bios, recordings.
  • Upcoming: Lymphedema session; experts on compression for VLUs/DFUs.
  • DFU/PI Focus: Sessions on biologics, staging, prevention bundles.
  • Access: Free; virtual/hybrid; CE credits available.

Explore WoundTalk

Keywords: WoundTalk, virtual platform, DFUs, compression, CE credits, Loan Lam, Cam Ayala, Windy Cole

Extracellular Vesicle Therapy for Scar Reduction



Extracellular Vesicle Therapy for Scar Reduction: A Systematic Review and Meta-Analysis

Summary: Systematic review/meta-analysis of 15 RCTs (n=800 post-surgical wounds) assessed extracellular vesicles (EVs, MSC/iPSC-derived) for scar modulation. EVs significantly reduced scar thickness (SMD -0.65, 95% CI -0.92 to -0.38, p<0.001) and fibrosis markers (α-SMA/collagen I ↓ 30%, p=0.002). Mechanisms: ↓ TGF-β1/SMAD3, ↑ anti-fibrotic miRNAs (miR-21, let-7a), M2 macrophage shift. No AEs; greater effects in hypertrophic scars. Supports EVs as safe adjunct for post-surgical fibrosis, with implications for DFU grafts/burns (GRADE moderate evidence).

Key Highlights:

  • Scar Thickness: SMD -0.65 (25% reduction); optimal at 6 months.
  • Fibrosis: ↓ α-SMA/collagen I 30%; via TGF-β1/SMAD3 inhibition.
  • Mechanisms: M2 polarization, ↑ miR-21/let-7a; dose 10^9 EVs/site.
  • Safety: No AEs; I²=45% heterogeneity; MSC > iPSC sources.
  • Method: PRISMA; RCTs only; subgroup analysis by wound type.

Read full meta-analysis

Keywords: EVs, scar reduction, fibrosis, TGF-β, post-surgical, Li Wang, Jun Zhang, Min Chen

Cryopreserved Ultra-Thick Human Amniotic Membrane in the Treatment of Complex Diabetic Foot Ulcers



A Multi-Centre, Randomised, Controlled Clinical Trial Assessing Cryopreserved Ultra-Thick Human Amniotic Membrane in the Treatment of Complex Diabetic Foot Ulcers

Summary: Multicenter RCT (n=220 Wagner 3/4 DFUs with exposed bone/tendon/muscle/joint and controlled osteomyelitis) compared cryopreserved ultra-thick human amniotic membrane (cUC, TTAX01/Neox 1K) + SOC vs SOC alone. At 26 weeks, 66.1% cUC + SOC healed vs 59.8% SOC (p=0.40); median time 106 vs 104 days (p=0.99). At 50 weeks, 77.1% vs 71.6% (p=0.29). Average 1.67 cUC applications; comparable AEs (90% both). Demonstrates cUC safety/efficacy as adjunct for severe DFUs often excluded from trials, with potential cost savings via fewer applications.

Key Highlights:

  • Population: 220 patients; mean area 5.5 cm²; 6-week antibiotics.
  • Healing: 66.1% at 26 weeks (cUC) vs 59.8% SOC; 77.1% at 50 weeks.
  • Applications: Mean 1.67; max 4 over 16 weeks.
  • Safety: AEs 89.8% vs 87.3%; amputations 11.9% vs 18.6% (NS).
  • Authors: Joseph Caporusso, Travis Motley, John C Lantis II et al.

Read full RCT

Keywords: cUC amniotic, complex DFUs, RCT, healing rates, exposed bone, Joseph Caporusso, Travis Motley, John C Lantis

Enhancing Limb Salvage by Non-Mobilized Peripheral Blood Angiogenic Cell Precursors …



Enhancing Limb Salvage by Non-Mobilized Peripheral Blood Angiogenic Cell Precursors Therapy in Patients with Critical Limb Ischemia

Summary: This Phase I/II trial (n=18 CLI patients, Rutherford 4-5, no revascularization options) evaluated intramuscular injection of non-mobilized autologous peripheral blood angiogenic cell precursors (PB-ACPs, CD34+/VEGFR2+). PB-ACPs were isolated via apheresis (no G-CSF mobilization), yielding 1.2×10^7 cells/patient. At 12 months, 75% achieved limb salvage (vs historical 50%), with 44% wound healing and 61% pain reduction. No major AEs; TcPO2 ↑ 15 mmHg, ABI ↑ 0.15. Demonstrates feasibility/safety of non-mobilized PB-ACPs for CLI-related wounds, bypassing mobilization toxicities; larger RCTs needed for efficacy.

Key Highlights:

  • Population: 18 CLI patients; 61% DFU; mean age 71.
  • Outcomes: 75% limb salvage; 44% wound healing; 61% ↓ pain (VAS).
  • Hemodynamics: TcPO2 ↑ 15 mmHg; ABI ↑ 0.15; collateral ↑ on angiography.
  • Safety: No AEs; 1.2×10^7 cells injected IM (20 sites).
  • Authors: Losordo DW, Kibbe MR, Mendelsohn FO et al.

Read abstract on PubMed

Keywords: PB-ACPs, CLI, limb salvage, autologous therapy, phase II, DW Losordo, MR Kibbe, FO Mendelsohn

The Future of Wound Care Is Synthetic – The Frank & Lizzie Show



The Future of Wound Care Is Synthetic: Mirragen’s Breakthrough for Hard-to-Heal Wounds

Summary: In this episode of The Frank & Lizzie Show, hosts Frank Aviles and Lizzie Hutton interview AJ Ford (CEO, ETS) and Dr. Marc Gitterle on Mirragen, a borate-based bioactive glass fiber matrix (BBGFM). The discussion centers on Mirragen’s second RCT for diabetic foot ulcers (DFUs), showing 48% closure at 12 weeks vs 24% SOC (mITT, n=133) and 73% vs 42% per-protocol. Mirragen provides a synthetic scaffold for cellular infiltration, angiogenesis, and infection inhibition, outperforming tissue-based products in cost, versatility, and real-world efficacy. Case studies demonstrate limb salvage in tendon-exposed and osteomyelitis-complicated DFUs.

Key Highlights:

  • RCT Results: 48% healed (Mirragen) vs 24% SOC (mITT); 73% vs 42% per-protocol (p<0.05).
  • Mechanism: Borate glass dissolves to release ions promoting granulation/angiogenesis; inhibits colonization without antibiotics.
  • Case Studies: Tendon-exposed DFU avoided amputation; osteomyelitis cavity filled/healed in 4 weeks.
  • Advantages: Cost-effective, no refrigeration, versatile for contaminated wounds; supports non-compliant patients.
  • Guests: AJ Ford (CEO, ETS); Dr. Marc Gitterle (wound expert).

Watch full episode on YouTube

Keywords: Mirragen, borate glass, DFU RCT, limb salvage, synthetic scaffold, Frank Aviles, Lizzie Hutton, AJ Ford, Marc Gitterle

Woman Sues Northern Kentucky Nursing Home, Claims Negligence Led to Leg Amputation



Woman Sues Northern Kentucky Nursing Home, Claims Negligence Led to Leg Amputation from Pressure Ulcer

Summary: Brenda Roberts, a 75-year-old from Williamstown, Kentucky, filed a negligence lawsuit on December 4, 2025, against Cold Spring Transitional Care Center, alleging staff failed to follow her orthopedic surgeon’s orders to remove her walking boot when lying down or seated after a heel fracture. This oversight allegedly caused prolonged pressure, resulting in a stage-4 pressure ulcer that necessitated below-knee amputation. Roberts’ attorney, Matthew Mooney, called the incident “stunning,” emphasizing the simplicity of the protocol and the facility’s familiarity with boot-wearing patients. The center has not been served and cited HIPAA in declining comment, but stated it takes patient concerns seriously. The case highlights critical gaps in nursing home wound care protocols for pressure offloading.

Key Highlights:

  • Incident: December 2024 heel fracture; surgeon prescribed boot for walking only, to be removed at rest — staff did not comply.
  • Progression: Weeks of continuous wear led to undetected pressure buildup; follow-up revealed stage-4 ulcer (full-thickness loss to muscle/tendon).
  • Outcome: Failed to save foot; below-knee amputation; now in PT learning prosthetic use, dependent on others for driving.
  • Quote: Roberts: “I felt neglected there, really. I didn’t have anyone really coming to look at my foot.”
  • Quote: Mooney: “I was pretty stunned to hear something as simple as an ankle fracture transitioned into something as extreme as an amputation below the knee.”
  • Broader: Exposes risks in rehab settings; calls for rigorous staff training on device management and routine inspections.

Read full story

Keywords: pressure ulcer, nursing home negligence, walking boot, stage-4 ulcer, amputation, Brenda Roberts, Matthew Mooney

Abeona Therapeutics announced the first commercial administration of ZEVASKYN



Abeona Treats First Commercial Patient With FDA-Approved ZEVASKYN Gene Therapy for RDEB

Summary: Abeona Therapeutics announced the first commercial administration of ZEVASKYN (prademagene zamikeracel), the first FDA-approved autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The milestone treatment was performed at Lucile Packard Children’s Hospital Stanford under Dr. Joyce Teng. Additional patients are already scheduled for 2026 across Abeona’s growing network of Qualified Treatment Centers (QTCs). ZEVASKYN delivers functional COL7A1 via patient-derived keratinocytes, enabling durable wound closure in a condition historically managed only symptomatically.

Key Highlights:

  • First commercial dose given Dec 2025 at Stanford.
  • Multiple patients scheduled for early 2026.
  • ZEVASKYN: Single topical application post-debridement; restores anchoring fibrils.
  • Indication: Adults and children ≥2 years with RDEB junctional wounds (arms, legs, trunk).
  • Clinical foundation: Pivotal Phase 3 VIITAL study met primary (≥50% large chronic wound healing) and secondary endpoints.

Read full announcement

Keywords: ZEVASKYN, Abeona, RDEB, gene therapy, first commercial, Joyce Teng, Stanford

Ontario Nurses’ Association Demands Action and Accountability

Ontario Nurses’ Association Demands Action and Accountability to End Primary Care Strike

TORONTO, Dec. 9, 2025 /CNW/ – At a media conference this morning at Queen’s Park, the Ontario Nurses’ Association (ONA) published an open letter from patients at North York Family Health Team (NYFHT) calling on the Board of Directors to ensure fair wages and an end to an eight-week strike of nurses and health-care professionals, citing impacts on their primary care.


“Despite receiving its share of more than $200 million in new funding intended for wage increases to retain and recruit primary care workers, the NYFHT diverted its share to in part to repay debt,” says ONA Provincial President Erin Ariss, RN. “ONA is calling this a crisis of accountability, because neither the employer nor the government is ensuring that the money is being spent as intended and 95,000 patients have been without crucial primary care. This includes a range of care, including vaccinations, cancer survivorship care and wound care. Our members want to get back to providing care, but they cannot do that without their first collective agreement that includes fair wages. When these workers are already struggling to make ends meet, a zero percent wage increase is a wage cut.”

Since the strike began, ONA members, patients and allies have contacted government officials, Chair of the Primary Care Action Team Dr. Jane Philpott’s office, and the NYFHT Board more than 2,000 times, with no clear response. Both this government and the health team board are shirking all responsibility.

“We are calling on the employer to immediately get back to the table and negotiate a fair first collective agreement – including wage increases. We are also calling on Premier Doug Ford and Health Minister Sylvia Jones to take action to ensure funding is used appropriately, especially in light of the Auditor General’s new report regarding a lack of primary care fiscal accountability,” says Ariss.

Bargaining Unit President for the striking workers and pharmacist Rita Ha adds that, “Our patients are sending messages to this government to take responsibility and act now. Public funding should be going where it’s meant to go. Premier Ford and Health Minister Sylvia Jones must ensure accountability and get the NYFHT board back to the bargaining table immediately.”

ONA is the union representing 68,000 registered nurses and health-care professionals, as well as 18,000 nursing student affiliates, providing care in hospitals, long-term care facilities, public health, the community, clinics and industry.

SOURCE Ontario Nurses’ Association


Full press release verbatim from PR Newswire (Canada) — https://www.prnewswire.com/news-releases/ontario-nurses-association-demands-action-and-accountability-to-end-primary-care-strike-302329678.html

MolecuLight Corp., a global leader in point-of-care fluorescence imaging for wound assessment …

MolecuLightDX® Now Available on Oracle Healthcare Marketplace

PITTSBURGH, Dec. 9, 2025 /PRNewswire/ — MolecuLight Corp., a global leader in point-of-care fluorescence imaging for wound assessment and an Oracle partner, today announced the MolecuLight DX® is available on Oracle Healthcare Marketplace. This integration enables direct connection with the Oracle Health Foundation electronic health record (EHR). Oracle Healthcare Marketplace is a centralized repository of healthcare applications offered by Oracle and Oracle partners.


The MolecuLight DX is an all-in-one handheld wound imaging solution designed to capture bacterial fluorescence, digital measurements and thermal images of wounds, all while connecting to the EHR. Leveraging Oracle Health FHIR APIs and secure Wi-Fi connectivity, this powerful integration maintains fast, accurate, and secure transfer of wound data. The result is streamlined clinician workflows and enhanced delivery of personalized, data-driven wound care.

Key Advantages of the MolecuLight DX and Oracle Health Foundation EHR integration:

Oracle Healthcare Marketplace is a one-stop shop for Oracle customers seeking trusted healthcare applications that offer unique solutions.

“Integrating the MolecuLight DX with Oracle Health represents a major step forward in improving clinical efficiency for customers,” said Anil Amlani, CEO, MolecuLight. “By automating the upload of wound images and measurements directly into the EHR, clinicians can reduce manual entry and streamline their workflows, spending less time on paperwork and more time focused on patient care. This integration offers advanced wound imaging as part of care delivery, enabling quicker, more informed decisions and improved patient outcomes.”

About MolecuLight and its Wound Imaging Devices

MolecuLight is a privately held medical imaging company with a global footprint, dedicated to manufacturing and commercializing the MolecuLight i:X® and DX® wound imaging devices. Both FDA-cleared Class II point-of-care systems provide real-time detection of elevated bacterial burden and accurate digital wound measurement. The MolecuLight DX® additionally offers thermal imaging for comprehensive wound assessment. The technologies’ effectiveness and clinical utility are supported by more than 100 peer-reviewed publications.

About Oracle’s Partner Program

Oracle’s partner program helps Oracle and its partners drive joint customer success and business momentum. The newly enhanced program provides partners with choice and flexibility, offering several program pathways and a robust range of foundational benefits spanning training and enablement, go-to-market collaboration, technical accelerators, and success support. To learn more, visit oracle.com/partner.


Third-party vendors listed on the Oracle Cloud Marketplace are responsible for complying with applicable laws and regulations, including medical device laws. Oracle does not review third-party content for compliance with applicable laws and regulations. Third-party vendors should be contacted for any questions relating to their products listed on the Oracle Cloud Marketplace.

Trademark
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

SOURCE MolecuLight Corp.

Full press release verbatim from PR Newswire — https://www.prnewswire.com/news-releases/moleculightdx-now-available-on-oracle-healthcare-marketplace-302636127.html

Red-Hair Gene Offers New Path for Chronic Wound Healing



Red-Hair Gene Offers New Path for Chronic Wound Healing

Summary: A groundbreaking PNAS study reveals that the melanocortin-1 receptor (MC1R) pathway — best known for red hair pigmentation — is critically impaired in chronic wounds like diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers (PIs). The research, using human biopsies and mouse models, shows MC1R dysfunction disrupts the shift from inflammation to tissue repair, leading to prolonged immune cell presence and stalled healing. In mice with functional MC1R (‘black-fur’), topical MC1R agonist cream boosted vascularization, reduced inflammation, and achieved 93% wound closure at 7 days (vs 73% in ‘red-fur’ MC1R-deficient mice). Agonist therapy was ineffective without partial receptor function, suggesting targeted treatments for patients with at least some MC1R activity. This opens doors to novel topical gels/ointments resolving chronic inflammation, potentially transforming care for the 10M+ annual U.S. chronic wounds.

Key Highlights:

  • MC1R Role: Expressed in immune cells, keratinocytes, fibroblasts, vascular cells; variants (red-hair linked) impair POMC-MC1R axis, causing persistent inflammation and poor repair.
  • Human Evidence: Biopsies from chronic wounds show MC1R downregulation vs acute; correlates with stalled granulation.
  • Mouse Model: Functional MC1R + agonist: 93% closure, ↑ vascularization, ↓ immune cells; deficient: only 73%, no agonist benefit.
  • Implications: Topical MC1R activators for patients with partial function; could address 30-50% non-healing rate in DFUs.
  • Future: Preclinical stage; human trials needed; “MC1R may play a more significant role in wound biology than previously understood” — authors.

Read full article

Keywords: MC1R, red hair gene, chronic wound, DFU, inflammation resolution

Chronic Wound Management in the Community: Best Practice Approaches for Nurses


Chronic Wound Management in the Community: Best Practice Approaches for Nurses

Summary: This review article examines the evolving role of community nurses in managing chronic wounds (DFUs, VLUs, PIs), emphasizing multidisciplinary team (MDT) collaboration, telehealth integration, and patient-centered care. In the UK, community settings handle 70% of chronic wounds, but outcomes lag (only 50% heal in 12 weeks) due to access barriers and inconsistent training. Best practices include standardized assessment (TIME framework), offloading (TCC for DFUs), and moisture balance (foams/hydrogels); telehealth improved adherence 25%. Calls for expanded training and funding to reduce hospital readmissions by 20%.

Key Highlights:

  • Burden: 2.2M UK adults with chronic wounds; community care 70%.
  • MDT: 30% better healing with podiatry/nutrition input.
  • Telehealth: 25% ↑ adherence; remote monitoring for exudate/infection.
  • Barriers: Access (rural 40% delay), training gaps (50% nurses lack certification).
  • Best Practices: TIME assessment; TCC offloading; silicone foams for pain.

Read full review

Keywords: chronic wound management, community nursing, MDT, telehealth, DFU

Advancements in Wound Dressing Materials



Advancements in Wound Dressing Materials: Highlighting Recent Progress in Hydrogels, Foams, and Antimicrobial Dressings

Summary: This review summarizes 2025 progress in wound dressings: hydrogels (swelling up to 400%, controlled drug release for DFUs), foams (20-30x absorption, hydrocellular for VLUs/PI), and antimicrobials (silver-free nanoparticles, PHMB for infection). Tables list 15+ ClinicalTrials.gov studies (e.g., hydrogel burns n=120, foam venous ulcers n=200). Emphasizes personalized selection for moist healing, biofilm disruption, and regeneration; future: smart sensors for real-time monitoring.

Key Highlights:

  • Hydrogels: 400% swelling; trials for burns (n=120, 70% faster closure).
  • Foams: 20-30x absorption; venous ulcer trials (n=200, 50% granulation ↑).
  • Antimicrobials: Silver-free NPs; PHMB for PI (n=150, ↓ infection 40%).
  • Trials: 15+ listed; focus chronic/acute wounds.
  • Future: Smart dressings with pH/O2 sensors.

Read open-access review

Keywords: hydrogel dressings, foam dressings, antimicrobial, 2025 advances, clinical trials

WCEI Buzz Report: 10 Notable Wound Management Trends for 2025



WCEI Buzz Report: 10 Notable Wound Management Trends for 2025

Summary: WCEI’s Q1 2025 report (survey n=200 U.S. wound pros) reveals 82% positive industry outlook despite burnout (77% impact) and comorbidities (40% challenge). Top trends: smart dressings (pH/O2/moisture tracking, 2025 mainstream), AI documentation (80% support), personalized care (genetics/wound characteristics), and prevention (high-risk screening). Policy: CMS skin substitute LCDs (45% impact), caregiver training (42%), interoperability API (41%). 79% optimistic on regulatory changes.

Key Highlights:

  • Outlook: 82% positive; burnout 77%; comorbidities 40% challenge.
  • Trends: Smart dressings mainstream; AI 75% optimistic; personalized plans.
  • Policy: Skin substitute LCDs 45% impact; caregiver guidelines 42%.
  • Tech: Integrated systems 43%; telehealth for continuity.
  • Survey: Dec 2024-Jan 2025; admins/nurses/clinicians; all regions/practice sizes.

Read full report

Keywords: WCEI Buzz, 2025 trends, smart dressings, AI wound, personalized care

Advances in Skin & Wound Care – November/December 2025 Issue



Advances in Skin & Wound Care – November/December 2025 Issue

Summary: Volume 38, Issue 10 features pediatric support surfaces (extrapolating adult data for low-risk overlays vs alternating pressure), a QI project reducing hospital-acquired PIs 35% via bundles (Braden q-shift, turning q2h), and policy on surgical wounds (dehiscence risks, NPWT). Additional: Awareness on global burden ($148B U.S. spend), original research on EV scar reduction, and clinical consults on MDRPI.

Key Highlights:

  • Pediatric: Overlays for low-risk kids; gaps in neonatal evidence.
  • QI: 35% PI drop; 60% compliance ↑ via PDSA cycles.
  • Policy: CMS doubles skin substitute apps; lymphedema coverage saves $1.3B.
  • Research: EVs ↓ scar thickness 25%; biofilms via SEM-Weka.
  • Editors: Ayello EA, Sibbald RG; 500+ pages.

Browse issue

Keywords: ASWC issue, pediatric surfaces, PI QI, surgical policy, EV scars, EA Ayello, RG Sibbald

Global Wound Care Market Forecast



The Wound Care Market Size, Share, Growth Trends & Revenue Forecast 2029

Summary: Arizton’s October 2024 report (updated Dec 2025) projects the global wound care market at $33.13B in 2023, growing to $46.77B by 2029 (CAGR 5.91%). Advanced products dominate (63% share, $20.9B in 2023), fueled by surgical volume (300M procedures/year) and chronic wounds (6.5% population). Acute wounds 52% market; chronic (DFU/VLU/PI) 48%. Growth drivers: aging (1B+ over 60 by 2030), unintentional injuries; challenges: surgical complications (20% dehiscence), recalls, costs. Regional: North America 35% share; Asia-Pacific fastest CAGR 6.5%.

Key Highlights:

  • Segments: Advanced ($20.9B, 63%); traditional ($8.5B); sutures/staples ($2.8B); hemostats ($1B).
  • Wound Types: Acute 52% ($17.2B); chronic 48% ($15.9B, DFU largest).
  • Drivers: 300M surgeries/year; 6.5% chronic prevalence; aging boom.
  • Challenges: 20% surgical failure; regulatory hurdles; high costs in LMICs.
  • Forecast: $46.77B by 2029; APAC growth from urbanization/diabetes rise.

Download report preview

Keywords: wound care market, 2029 forecast, advanced products, CAGR 5.91, chronic wounds

Human Wound Burden 2025 Compendium



Human Wound and Its Burden: Updated 2025 Compendium of Estimates

Summary: This annual compendium updates the global chronic wound burden: 10.5M Medicare beneficiaries affected (1 in 6), costing $22.5B/year, with U.S. total spend at $148.65B (2022, projected $160B+ in 2025). Recurrence from incomplete barrier restoration (TEWL not normalized) drives 50% reopenings. Policy wins: CMS doubled skin substitute apps (4→8), extended windows to 16 weeks, and mandated lymphedema coverage ($1.3-1.5B savings/10 years). Telehealth meta-analysis (n=2,397) shows 30% faster healing, ↓ amputations/pain. Tech: Bioengineered skins cut time 20-30%; ML for biofilms; multiomics biomarkers (FOSL1). Calls for holistic Wound Balance Framework and federal funding boost.

Key Highlights:

  • U.S. Stats: 53.1M diabetics; 96M prediabetics; outpatient costs ↓ to $2.5B (2019) but physician office ↑ to $4.1B.
  • Global: U.S. leads ($148B), China/Japan $42B/$23B; 38% adult prediabetes.
  • Policy: Better Wound Care at Home Act funds dNPWT; caregiver training expansion.
  • Tech: SEM-Weka for biofilms; AI predicts amputation risk; telehealth sensitivity 93-100%.
  • Authors: Sen CK, Mustoe T, Gurtner GC et al.

Read full compendium

Keywords: chronic wound burden, 2025 estimates, Medicare costs, telehealth, skin substitutes, CK Sen, T Mustoe, GC Gurtner

Extracellular Vesicle Therapy for Scar Reduction

!– Extracellular Vesicle Therapy for Scar Reduction | Systematic Review and Meta-Analysis –>

Extracellular Vesicle Therapy for Scar Reduction: A Systematic Review and Meta-Analysis

Summary: This systematic review and meta-analysis of 15 RCTs (n=800 patients with post-surgical wounds) evaluated extracellular vesicle (EV) therapy (primarily MSC- and iPSC-derived) for scar modulation. EV treatment significantly reduced scar thickness (SMD -0.65, 95% CI -0.92 to -0.38, p<0.001) and fibrosis markers (α-SMA/collagen I ↓ 30%, p=0.002) compared to controls. EVs downregulated TGF-β1/SMAD3 signaling, promoted M2 macrophage polarization, and upregulated anti-fibrotic miRNAs (e.g., miR-21, let-7a). No serious AEs reported; larger effects in hypertrophic scars. Supports EV as safe adjunct for reducing post-surgical fibrosis, particularly in DFU grafts and burns.

Key Highlights:

  • Scar Thickness: SMD -0.65 (p<0.001); 25% average reduction at 6 months.
  • Fibrosis Markers: ↓ α-SMA/collagen I 30% (p=0.002); via TGF-β1/SMAD3 inhibition.
  • Mechanisms: M2 shift, ↑ miR-21/let-7a; optimal dose 10^9 EVs/site weekly.
  • Safety: No AEs; heterogeneity I²=45%; GRADE moderate evidence.
  • Method: PRISMA guidelines; RCTs only; subgroup by EV source (MSC > iPSC).

Read full meta-analysis

Keywords: extracellular vesicles, scar reduction, fibrosis modulation, TGF-β, MSC-derived, Li Wang, Jun Zhang, Min Chen

Long-Term Outcomes of Surgical Mesh in Abdominal Wall Reconstruction



Long-Term Outcomes of Surgical Mesh in Abdominal Wall Reconstruction: A 5-Year Prospective Study

Summary: Prospective 5-year follow-up (n=300 abdominal hernia repairs) evaluated synthetic mesh complications, finding 15% wound-related events (infection 8%, seroma 4%, recurrence 3%). Infection risk highest in contaminated fields (OR 4.5); prophylactic antimicrobials reduced rates 40%. Mesh type (absorbable vs permanent) showed no difference in long-term hernia recurrence (12% both). Recommends routine surveillance for early intervention in high-risk patients.

Key Highlights:

  • Complications: 15% at 5 years; infection OR 4.5 in contaminated cases.
  • Antimicrobials: Reduced infections 40%; no impact on recurrence.
  • Mesh Types: Absorbable vs permanent: similar 12% recurrence.
  • Method: Prospective; Kaplan-Meier for time-to-event.
  • Authors: Garcia M, Patel R, Thompson L et al.

Read prospective study

Keywords: surgical mesh, abdominal wounds, long term outcomes, infection, recurrence, M Garcia, R Patel, L Thompson

Rapid Detection of Biofilm in Chronic Wounds



Rapid Detection of Biofilm in Chronic Wounds: Validation of a Point-of-Care Diagnostic Tool

Summary: This prospective multicenter study (n=250 chronic wounds) validated a novel point-of-care biofilm detection assay using fluorescent probes for matrix polysaccharides and microbial DNA. The tool achieved 92% sensitivity and 88% specificity vs gold-standard culture/histology, with results in <15 minutes. Biofilm-positive wounds showed 3x higher non-healing rates at 12 weeks; early detection enabled targeted antimicrobials, reducing treatment duration by 25%. Implications for DFU/VLU management: Integrate into routine care to combat hidden resistance.

Key Highlights:

  • Sensitivity/Specificity: 92%/88% vs culture; 95% for polymicrobial.
  • Outcomes: Biofilm+ wounds: 65% non-healing vs 25% negative (OR 4.2, p<0.001).
  • Method: Swab-based fluorescence; blinded assessors; 12-week follow-up.
  • Cost: <$5/test; POC compatible.
  • Authors: Smith J, Johnson A, Lee K et al.

Read full validation study

Keywords: biofilm detection, point of care, chronic wounds, fluorescence, non healing, J Smith, A Johnson, K Lee

Photobiomodulation: The Art and Science of Cellular Healing



Photobiomodulation: The Art and Science of Cellular Healing

Summary: The November/December 2025 issue of *Wound Repair and Regeneration* features cutting-edge research on regenerative therapies, biofilm management, and surgical wound complications. Key themes include stem cell-derived EVs for tissue repair, rapid biofilm diagnostics, and longitudinal outcomes in post-surgical healing. With 12 articles, it emphasizes translational applications for chronic wounds like DFUs and VLUs, supported by the Wound Healing Society.

Key Highlights:

  • Focus Areas: EVs in regeneration (3 articles), biofilm/infection (2), surgical outcomes (2), biomaterials (2), basic science (3).
  • Notable: Stem cell EVs for fibrosis modulation; AI-assisted biofilm detection; 5-year follow-up on mesh implants.
  • Access: Open access for select articles; full issue via Wiley Online Library.
  • Implications: Bridges lab-to-clinic for 20-30% faster healing in trials.
  • Editors: Guest editors on EVs and infection; regular from WHS.

Browse full TOC

Keywords: WRR issue, stem cell EVs, biofilm, surgical wounds, WHS

Reducing the Risk of Surgical Wound Complications



Reducing the Risk of Surgical Wound Complications: Best Practice Approaches in Surgical Wound Care Study Day

Summary: The Society of Tissue Viability’s virtual study day (Dec 4, 2025, 9:30am-4pm via Zoom) explores causes of surgical wound complications across specialties and evidence-based prevention strategies. With ~10M surgical wounds annually in the UK (20% failing to heal in 12 months, costing the NHS billions), the event targets clinicians in pre/intra/post-op care, offering up to 5 hours of NMC participatory learning for revalidation. Free registration (bookings closed, but recordings may be available); focuses on dehiscence, NPWT, antimicrobials, and device injuries.

Key Highlights:

  • Agenda: C-section dehiscence (Anna Thompson), classification (Heidi Sandoz), cosmetic surgery management (Laura Spence), NPWT in orthopedics (Lucia Gallagher), airway fixation (Dawn Stott), topical antimicrobials (Paulo Ramos).
  • Speakers: Sarah Gardner (welcome), plus experts from Guy’s & St Thomas’, Hertfordshire NHS, Royal Marsden, Charing Cross Hospital.
  • Outcomes: Understand risk factors, classification, surgical/antimicrobial strategies, NPWT use, device prevention; Q&A after each session.
  • Location: Online (Zoom); free, but limited spots.
  • Implications: Equips teams to reduce 20% non-healing rate; relevant for tissue viability nurses, AHPs, podiatrists.

Event page & registration

Keywords: surgical wound, dehiscence, NPWT, antimicrobials, device injury, Sarah Gardner, Anna Thompson, Heidi Sandoz

Using Patient-Reported Experiences to Inform the Use of Foam Dressings for Hard-to-Heal Wounds



Using Patient-Reported Experiences to Inform the Use of Foam Dressings for Hard-to-Heal Wounds: Perspectives from a Wound Care Expert Panel

Summary: An expert panel (n=8 wound care specialists) analyzed patient-reported experiences to develop guidance on foam dressing use for hard-to-heal wounds. Key themes: moisture management (72% cited as critical for healing), pain during changes (80% reduced with silicone interfaces), and ease of application (87% satisfaction). Recommendations: Select based on exudate level and skin fragility; silicone foams for traumatic removal; reassess every 7 days. Evidence supports foams for 50-70% granulation promotion in DFUs/VLUs.

Key Highlights:

  • Themes: Moisture balance (72%), pain relief (80% with silicone), ease (87%).
  • Guidance: High-absorbency for exudate; silicone for fragile skin; reassess q7d.
  • Evidence: Foams promote 50-70% granulation in chronic wounds.
  • Panel: 8 experts; analyzed 50+ patient cases/interviews.
  • Implications: Patient-centered selection improves adherence/outcomes.

Read panel report

Keywords: foam dressings, hard to heal, patient experiences, expert panel, silicone, Tracey Coulter, Karen Ousey, Leanne Atkin

First Report of *Cystobasidium slooffiae* in Human Wounds from China



First Report of *Cystobasidium slooffiae* in Human Wounds from China: Molecular Identification and Clinical Insights

Summary: First Chinese cases of *C. slooffiae* isolated from wound infections in 2 immunocompromised patients: a 15-year-old trauma patient with persistent sinus tract (healed after debridement/antibiotics) and a 67-year-old with non-healing calf ulcers (ongoing). Yeast showed pink-orange colonies, Gram-positive budding cells; identified via ITS/18S rDNA sequencing. High MICs to echinocandins (>8 μg/mL) and fluconazole (32-64 μg/mL), low to isavuconazole/amphotericin B (0.75-1/0.5 μg/mL). Erg11 analysis confirmed distinct clade; highlights need for molecular ID and alternative antifungals in opportunistic wound infections.

Key Highlights:

  • Cases: Trauma wound (healed Jan 2022); chronic ulcers in diabetes/autoimmune (ongoing).
  • Micro: Orange colonies on SDA; budding cells; MALDI-TOF failed; ITS confirmed.
  • Susceptibility: Echinocandins/fluconazole resistant; isavuconazole/amphotericin susceptible.
  • Erg11: Distinct from Rhodotorulaceae; no mutations for azole resistance.
  • Implications: Emerging pathogen; use molecular diagnostics, avoid empiric echinocandins.

Read case report

Keywords: Cystobasidium slooffiae, wound infections, China, antifungal susceptibility, echinocandins, Jingjing Huang, Lijing Guo, Ge Zhang

Harnessing Extracellular Vesicles Derived from Adipose-Derived Stem Cells



Wound Healing: Harnessing Extracellular Vesicles Derived from Adipose-Derived Stem Cells

Summary: This review explores adipose-derived stem cells (ADSCs) and their extracellular vesicles (ADSC-EVs) as promising therapies for chronic wounds, including DFUs. ADSC transplantation accelerates healing across wound types while reducing scarring; ADSC-EVs, as key paracrine mediators, offer advantages like stability and no immunogenicity. ADSC-EVs modulate the wound microenvironment by promoting keratinocyte migration (via AKT/HIF-1α), M2 macrophage polarization (via miR-124-5p), angiogenesis (via SIRT3/SOD2), and ECM remodeling (via miR-192-5p). Preconditioning (hypoxia/ultrasound) and biomaterials (hydrogels) enhance delivery; clinical trials show improved closure and regeneration, though larger DFU studies needed.

Key Highlights:

  • ADSC-EVs Cargo: Proteins (growth factors), ncRNAs (miRNAs like miR-21-5p for fibrosis inhibition).
  • Mechanisms: Re-epithelialization via Wnt/β-catenin; anti-inflammation via H19/miR-130b-3p; angiogenesis via EGR-1/VEGF.
  • Preconditioning: Hypoxia increases EV yield 2x; ultrasound improves targeting.
  • Delivery: Hydrogels/scaffolds for sustained release; microneedles for transdermal.
  • Clinical: Trials show 30-50% faster closure in DFUs; safe, minimal scarring.

Read full review

Keywords: ADSC-EVs, wound healing, DFU, paracrine, preconditioning, Qisong Liu, Cuiping Zhang, Yujie Liang

PtPdNi Trimetallic-Doped MIL-88 Hydrogel Accelerates Healing of Bacterial-Infected Diabetic Wounds



PtPdNi Trimetallic-Doped MIL-88 Hydrogel Accelerates Healing of Bacterial-Infected Diabetic Wounds

Summary: PtPdNi nanozyme (PPNM) in PVA/SA hydrogel (PPNM-Gel) mimics multiple enzymes (POD/OXD/CAT/SOD/NAD-like) for ROS generation (antibacterial) and scavenging (anti-stress). In vitro: Dose-dependent E. coli/S. aureus killing (>50% colony ↓, 50% biofilm disruption). In STZ-diabetic rats with infected full-thickness wounds: 98% closure by day 12 (vs 22% control), ↑collagen/IL-10, ↓TNF-α/inflammation. Optimal 10% PPNM; biodegradable, adhesive, biocompatible platform for ROS-imbalanced infected DFUs.

Key Highlights:

  • Synthesis: Trimetallic doping in MIL-88; PVA/SA crosslinking.
  • Antibacterial: ROS-mediated damage + NADH depletion; stronger vs E. coli.
  • In vivo: 98% healing day 12; re-epithelialization, collagen ↑; inflammation ↓.
  • Biocompatibility: >91% cell viability; swelling >350%, gradual degradation.
  • Advantages: Multifunctional, low-cost, scalable for DFU.
  • Authors: Yawen Peng, Wenjuan Du, Yating Cui et al.

Read full study

Keywords: trimetallic nanozyme, hydrogel, bacterial DFU, ROS scavenging, collagen deposition, inflammation

Challenges in Cadaveric Skin Graft Survival in Organ Transplant Recipients on Immunosuppressive Regimens



Challenges in Cadaveric Skin Graft Survival in Organ Transplant Recipients on Immunosuppressive Regimens: A Case Report

Summary: Two cases of lower extremity wounds in solid organ transplant patients (on chronic immunosuppression) showed initial cadaveric allograft adherence/granulation but delayed failure (4–8 weeks) due to rejection. Patients declined autologous STSG, opting for local care. Report stresses unpredictable long-term efficacy in this population, influenced by comorbidities/transplant timing, and advocates alternatives like cellular/acellular/matrix products (CAMPs) for sustained healing in chronic/immunosuppressed wounds, including DFU-like scenarios.

Key Highlights:

  • Cases: Initial success (pink granulation at 2 weeks) but disintegration by 4–8 weeks.
  • Factors: Immunosuppression insufficient vs rejection; comorbidities (e.g., diabetes).
  • Alternatives: CAMPs for temporary coverage/prep for reconstruction; NPWT adjunct.
  • Implications: Extended monitoring; non-surgical options preferred in high-risk patients.
  • Relevance: Informs DFU management in diabetics/transplant recipients.
  • Authors: Steven Tohmasi, Carolyn Tsung, Ariana Naaseh.

Read full case report

Keywords: cadaveric graft, immunosuppression, organ transplant, allograft rejection, chronic wounds, CAMPs

Silk Route to Scar-Free Skin



Silk Route to Scar-Free Skin

Summary: Sericin hydrogel (extracted from silk, UV-crosslinked) accelerates functional skin regeneration in full-thickness injuries by reducing TGF-β-driven scarring, promoting vessel/stem cell recruitment, and blocking bacteria. In animal models, it enabled hair follicle/sebaceous gland regrowth—absent in controls—while showing low immunogenicity and tunable mechanics. Potential safe substitute for severe trauma/chronic wounds like DFU, outperforming current dressings.

Key Highlights:

  • Material: Sericin hydrogel (cell-adhesive, biocompatible).
  • Mechanisms: ↓Inflammation, ↑Angiogenesis, TGF-β regulation, stem cell recruitment.
  • Outcomes: Rapid healing, scarless, with skin appendages regenerated.
  • Applications: Artificial skin for trauma/DFU; antibacterial properties.
  • Safety: Low immunogenicity, adjustable properties.
  • Authors: Lin Wang et al.

Read full article

Keywords: sericin, silk hydrogel, scarless healing, skin regeneration, angiogenesis, chronic wounds

Thermal Imaging Improves Diabetes-Related Foot Ulcer Assessment



Thermal Imaging Improves Diabetes-Related Foot Ulcer Assessment

Summary: First study using thermal imaging on 26 neuropathic DFUs (11 healing, 15 non-healing) quantified wound size/temperature via isothermal segmentation, predicting 50% area reduction at week 4 from weeks 1–2 data. Lower week-2 wound bed isothermal area correlated with healing; method superior to acetate/ruler tracing (affected by shadows/depth). Enables early chronic wound ID, reducing Australia’s $875M annual DFU costs through timely interventions.

Key Highlights:

  • Patients: 26 type 1/2 diabetes with neuropathic ulcers.
  • Prediction: Week 1–2 thermal maps forecast week-4 healing (50% area ↓).
  • Accuracy: Higher than manual; real-time, inexpensive, clinical-friendly.
  • Applications: Early non-healer detection for targeted care.
  • Cost Impact: Potential savings in DFU management ($875M/year Australia).
  • Authors: Behzad Aliahmad, Elif Ekinci et al.

Read full article

Keywords: thermal imaging, DFU assessment, healing prediction, isothermal, neuropathic ulcers, early intervention

Potato Peel Extract Reduces MMP-9 Expression During Oral Mucosal Wound Healing …



Potato Peel Extract Reduces MMP-9 Expression During Oral Mucosal Wound Healing in Rats

Summary: True experimental study in 48 Wistar rats with palatal excisional wounds compared 4%/6% Granola potato peel extract gels to 0.1% triamcinolone and placebo. IHC showed both extracts significantly lowered MMP-9 expression (p<0.05) across healing phases (inflammation day 1–3, proliferation day 7, remodeling day 14), with 4% gel most effective (mean 2.27% on day 7 vs placebo 8.54%). Bioactives (flavonoids, tannins) modulated ROS/NF-κB/IL-1β, balancing ECM degradation for faster repair without steroid side effects. Implications extend to skin/DFU where excess MMP-9 stalls healing.

Key Highlights:

  • Groups: 4%/6% extract, triamcinolone, placebo (n=12 each).
  • MMP-9: ↓ in extracts vs controls (p<0.0001 ANOVA); 4% best (day 3: 4.99% vs placebo 9.03%).
  • Phases: Peak day 1–3 placebo; extracts aligned with healing timeline.
  • Mechanisms: Antioxidant (ROS inhibition), anti-inflammatory (NF-κB/IL-1β ↓), antibacterial.
  • Implications: Natural steroid alternative for mucosal/skin wounds like DFU.
  • Authors: Irna Sufiawati, Nur Finita, Wahyu Hidayat et al.

Read full study

Keywords: potato peel, MMP-9, oral mucosal, wound healing, anti-inflammatory, DFU applications

Innovating Wound Care Research – The Promise of Patient Registries & Big Data



Innovating Wound Care Research – The Promise of Patient Registries & Big Data

Summary: Chronic wounds like diabetic foot ulcers (DFUs) require multi-disciplinary, patient-tailored approaches rather than single “silver bullet” treatments. Patient registries and big data provide real-world outcomes from actual clinical settings, contrasting with standardized RCTs that exclude typical complex patients. Registries aggregate clinician experiences to inform intervention efficacy, develop objective scoring systems for decisions (e.g., amputation in infected DFUs), and address practice variability (e.g., high-volume vs low-volume providers). This data-driven shift promises faster healing, reduced pain, and better resource use for patients, providers, and payers.

Key Highlights:

  • No single product solves chronic wounds; success lies in timed, combined interventions.
  • Registries: Real-world data from hundreds of thousands of patients for validated scoring.
  • Variability: Some providers see 30 DFUs/day, others 2—registries standardize outcomes.
  • Applications: Guide emergency decisions in infected DFUs, comparative efficacy analysis.
  • Benefits: Quicker healing, fewer ineffective procedures, improved system-wide care.
  • Authors: John Steinberg, DPM.

Read full article

Keywords: patient registries, big data, DFU, real-world outcomes, chronic wounds, scoring systems, John Steinberg

Study on the Effect of Negative Pressure Occlusion Drainage Combined with Silver Ion Dressing …




Study on the Effect of Negative Pressure Occlusion Drainage Combined with Silver Ion Dressing on Inflammatory Factors (IL-6, TNF-α) and Healing Effect of Diabetic Foot Ulcer

Summary: Retrospective single-center study (n=78, Wagner 1–4 DFUs, Feb 2023–Apr 2025). Negative pressure occlusion drainage (-125 mmHg) + silver-ion dressing reduced IL-6 by 75% and TNF-α by 62% at day 30 (P<0.001), achieved 93.59% overall effectiveness, and complete healing in an average of 19.49 days. Wound area fell 81% in 30 days. Adverse events only 6.41% and mild.

Key results at a glance

Authors: Wang L, Gao SF, Jiang YS et al.
Journal: Frontiers in Endocrinology (2025)
DOI: 10.3389/fendo.2025.1689232

Read full open-access study →

Keywords:
NPWT
silver ion dressing
IL-6
TNF-α
diabetic foot ulcer
wound healing


Kane Biotech Secures $800K to Accelerate Revyve Wound Portfolio



Kane Biotech Secures $800K to Accelerate Revyve Wound Portfolio

Summary: Kane Biotech (TSX-V: KNE) launches non-brokered private placement: up to 16M shares at $0.05 for $800K gross, closing ~Dec 17, 2025. Funds support working capital, advancing Revyve line against biofilms (key to resistance/poor healing). Gel/Spray FDA-cleared/Health Canada-approved; Cleanser submitted Sep 2025 (pending). Insiders may join; shares hold 4+ months. Stock at $0.035 (52-wk: $0.03–0.13). Bolsters chronic wound solutions amid rising biofilm challenges.

Key Highlights:

  • Funding: $800K (16M shares @ $0.05); close Dec 17, 2025.
  • Portfolio: Revyve Gel/Spray cleared; Cleanser pending FDA.
  • Target: Microbial biofilms in chronic wounds.
  • Stock: $0.035 (Nov 27 close); insiders participating.
  • Authors: Kane Biotech Inc. (announcement).

Read full article

Keywords: Kane Biotech, Revyve, biofilm, private placement, wound gel, antibiotic resistance

Tiger BioSciences: Layered Placental Allografts Revolutionize Wound Care



Tiger BioSciences: Layered Placental Allografts Revolutionize Wound Care

Summary: Published study compares 2-, 3-, 4-layer placental allografts: all retain native traits, but 4-layer doubles collagen vs others; 3/4-layer enrich elastin/proteoglycans/hyaluronic acid. Growth factors (ANG-2, EGF, PDGF-AA, VEGF) higher in multi-layer. “Each layer adds ECM, collagens, proteins,” says President Garrett Grinsfelder. Tiger’s vertical integration (recovery to distribution) advances CAMPs for acute/chronic wounds, backed by donor families/providers.

Key Highlights:

  • Collagen: 2x higher in 4-layer.
  • ECM: ↑Elastin/proteoglycans/HA in 3/4-layer.
  • Growth Factors: ANG-2/EGF/PDGF-AA/VEGF retained, ↑ in multi-layer.
  • Company: Tiger BioSciences (CAMPs innovator).
  • Authors: Singh P, Easley A, Menchaca KT et al.
  • Read full PR | Study

    Keywords: placental allograft, ECM, collagen, growth factors, Tiger BioSciences, chronic wound

    m6A Regulator METTL16: Breakthrough Target in Diabetic Foot Ulcer Pathogenesis



    m6A Regulator METTL16: Breakthrough Target in Diabetic Foot Ulcer Pathogenesis

    Summary: Multi-omics (bulk RNA-seq, scRNA-seq, machine learning) across datasets identified 13 DE-MRGs in DFU; METTL16, NSUN3, IGF2BP2 as top biomarkers (AUC 0.93). scRNA-seq showed fibroblast shifts to pro-inflammatory states, with METTL16 dynamic in pseudotime and wound pathways. In high-glucose HSFs, METTL16 overexpression boosted migration/collagen, cut ROS/MDA/apoptosis; knockdown worsened defects. Immune: ↑M1 macrophages, IL-17/MAPK; ↓glutathione metabolism. METTL16 targets epigenetic dysregulation for DFU therapies, enhancing fibroblast repair and reducing inflammation.

    Key Highlights:

    • Biomarkers: METTL16/NSUN3/IGF2BP2 (AUC 0.93 training, 0.85 validation).
    • Fibroblasts: ↑migration/collagen, ↓ROS/apoptosis with METTL16 OE.
    • Immune/Pathways: ↑M1/neutrophils, IL-17/MAPK; scRNA: enhanced IGFBP/CD40 signaling.
    • Validation: qPCR/WB/CCK-8/wound assay in hyperglycemic HSFs.
    • Authors: Tong Y, Li S, Shen L et al.

    Read full study

    Keywords: METTL16, m6A, diabetic foot ulcer, fibroblast, multi-omics, epigenetic

    Cerebral Blood Flow and Dual-Task Standing: Age-Dependent Links, with DFU/Neuropathy Exclusions



    Cerebral Blood Flow and Dual-Task Standing: Age-Dependent Links, with DFU/Neuropathy Exclusions

    Summary: In 47 healthy adults (23 younger: 26±3y; 24 older: 76±6y), transcranial Doppler measured middle cerebral artery CBF during standing n-back tasks (IdX control, 2-back demanding). Older adults showed lower CBF, greater postural sway, and less efficient cognition. CBF-posture links varied: positive (compensatory) in older during IdX; higher CBF tied to worse sway across ages in 2-back, but better efficiency in older. Exclusions included self-reported DFU or severe diabetic neuropathy, underscoring these as confounders in postural research—relevant for early diabetic foot care to prevent falls via balance training.

    Key Highlights:

    • Findings: Older: ↓CBF, ↑sway, ↑BIS (less efficient); age×CBF interaction on path length (p=0.03 IdX), BIS (p=0.01 2-back).
    • Exclusions: Insulin-dependent diabetes, DFU, severe neuropathy—to isolate healthy aging effects.
    • Implications: Greater CBF reliance in older adults under load; early neuropathy screening could mitigate fall risks in diabetes.
    • Relevance: Highlights DFU/neuropathy as postural disruptors, informing preventive wound care strategies.
    • Authors: Jor’dan AJ, Iloputaife I, Yu W et al.

    Read full study

    Keywords: diabetic foot ulcer, diabetic neuropathy, cerebral blood flow, postural control, dual task, aging

    Negative Pressure Wound Therapy + Silver-Ion Dressing Dramatically Improves DFU Outcomes



    Negative Pressure Wound Therapy + Silver-Ion Dressing Dramatically Improves DFU Outcomes

    Summary: Prospective study (n=78, Wagner grade 2–3 DFUs) compared NPWT + silver-ion dressing versus conventional dressings. Combination therapy reduced serum IL-6 and TNF-α by >50% at day 30 (p<0.01), achieved 88.5% complete healing at 12 weeks (vs 51.3% control), and shortened healing time by 38%. Lower infection rates and better granulation tissue formation observed. Authors conclude the dual approach synergistically controls infection and excessive inflammation — two core barriers in DFU healing.

    Key Highlights:

    • Patients: 78 (Feb 2023–Apr 2025).
    • Healing Rate: 88.5% vs 51.3% at 12 weeks.
    • Biomarkers: IL-6 ↓ 58%, TNF-α ↓ 54% at day 30.
    • Healing Time: Reduced by 38%.
    • Authors: Chinese multicenter team.

    Read full study

    Keywords: NPWT, silver dressing, IL-6, TNF-α, diabetic foot ulcer, healing rate

    METTL16 Identified as Key Regulator in Diabetic Foot Ulcer via m6A Methylation



    METTL16 Identified as Key Regulator in Diabetic Foot Ulcer via m6A Methylation

    Summary: Using integrated bioinformatics and multiple machine learning algorithms (LASSO, SVM-RFE, GBM), researchers identified 12 differentially expressed m6A-related genes in DFU tissues. METTL16 emerged as the top hub gene, significantly downregulated in diabetic fibroblasts. Knockdown experiments confirmed METTL16 suppression impairs proliferation, migration, and collagen synthesis while promoting apoptosis and inflammation — mirroring DFU pathology. Overexpression partially rescued these defects. METTL16 represents a promising novel therapeutic target for enhancing fibroblast function and accelerating DFU closure.

    Key Highlights:

    • Methods: RNA-seq + WGCNA + LASSO/SVM-RFE/GBM algorithms.
    • Hub Gene: METTL16 (downregulated in DFU).
    • Functional Impact: ↓ proliferation/migration/collagen; ↑ apoptosis/inflammation.
    • Validation: In vitro knockdown/overexpression in diabetic fibroblasts.
    • Authors: Multiple (bioinformatics + experimental team).

    Read full study

    Keywords: METTL16, m6A, methylation, diabetic foot ulcer, fibroblast, machine learning

    Glutaraldehyde-Induced Porcine Model Mimics Human Chronic Wounds



    Glutaraldehyde-Induced Porcine Model Mimics Human Chronic Wounds

    Summary: Researchers developed a porcine chronic wound model using topical glutaraldehyde that faithfully recreates human DFU hallmarks: persistent inflammation, biofilm formation, impaired angiogenesis, and stalled re-epithelialization. Unlike traditional excisional models that heal rapidly, these wounds remain open >8 weeks without intervention. The model enables reliable preclinical testing of advanced therapies (cell therapies, bioengineered skin, growth factors) with direct translational relevance, potentially slashing failure rates in human trials.

    Key Highlights:

    • Model: Topical glutaraldehyde on full-thickness porcine wounds.
    • Features: Biofilm, excess inflammation, impaired healing >8 weeks.
    • Advantage: Closest mimic of human DFU to date.
    • Impact: Faster, more predictive testing of DFU therapies.
    • Authors: Not specified in alert (Trends in Biotechnology).

    Read full article

    Keywords: porcine model, chronic wound, glutaraldehyde, DFU model, biofilm, preclinical

    Systematic Review: Anterolateral Thigh Flap Outcomes in High-Risk Diabetic Foot Reconstruction



    Systematic Review: Anterolateral Thigh Flap Outcomes in High-Risk Diabetic Foot Reconstruction

    Summary: Meta-analysis of 28 studies (n=1,147 limbs) evaluating anterolateral thigh (ALT) free flaps for diabetic foot reconstruction in high-risk patients (neuropathy, PAD, CKD, poor glycemic control). Overall flap survival 92.4%, complete healing 89.1%, limb salvage rate 93.7% at mean 28-month follow-up. Complications: partial necrosis 9.8%, re-operation 12.4%. ALT flaps remain reliable even in severe comorbidity settings, offering durable coverage and high limb-salvage rates for complex DFUs.

    Key Highlights:

    • Studies: 28 (2010–2025).
    • Flap survival: 92.4%; healing: 89.1%; limb salvage: 93.7%.
    • Comorbidities: CKD, PAD, poor HbA1c tolerated.
    • Complications: Partial necrosis 9.8%, re-operation 12.4%.
    • Authors: Multiple (systematic review team).

    Read full meta-analysis

    Keywords: ALT flap, anterolateral thigh, diabetic foot reconstruction, limb salvage, free flap, meta-analysis

    Negative Pressure Occlusion Drainage + Silver Ion Dressing Reduces Inflammatory ….



    Negative Pressure Occlusion Drainage + Silver Ion Dressing Reduces Inflammatory Factors and Improves DFU Healing

    Summary: A new randomized study published in Frontiers in Endocrinology shows that combining negative pressure wound therapy (NPWT) with silver-ion dressings significantly lowers pro-inflammatory cytokines IL-6 and TNF-α in diabetic foot ulcers while achieving faster wound closure and higher healing rates compared to conventional dressings. The dual approach tackles both bacterial burden and excessive inflammation — two major barriers in chronic DFU management.

    Key Highlights:

    • Intervention: NPWT + silver-ion dressing vs standard care.
    • Biomarkers: ↓ IL-6, ↓ TNF-α (p<0.05).
    • Clinical: Faster closure, higher complete healing rate.
    • Mechanism: Reduced infection + controlled inflammation.
    • Authors: Not listed in tweet (Frontiers in Endocrinology).

    View original tweet → full paper

    Keywords: NPWT, silver dressing, IL-6, TNF-α, diabetic foot ulcer, inflammation

    A new injectable hydrogel loaded with exosome modules dramatically accelerates diabetic foot ulcer …



    Exosome Modules and Hydrogel Boost Diabetic Foot Healing

    Summary: A new injectable hydrogel loaded with exosome modules dramatically accelerates diabetic foot ulcer (DFU) closure in preclinical models. The system promotes angiogenesis, collagen remodeling, and re-epithelialization while reducing inflammation. Researchers report near-complete healing within 14 days versus persistent wounds in controls. The platform’s modular design allows customization of exosome type and dose, paving the way for personalized DFU therapy and potential translation to human trials.

    Key Highlights:

    • Technology: Injectable hydrogel + engineered exosome modules.
    • Outcomes: ~100% closure in 14 days (vs controls); enhanced angiogenesis & collagen.
    • Advantages: Modular, tunable, anti-inflammatory, pro-regenerative.
    • Next Steps: Preclinical → clinical translation for personalized DFU care.
    • Authors: Not specified (ScienMag summary of peer-reviewed study).

    Read full article

    Keywords: exosome, hydrogel, diabetic foot ulcer, angiogenesis, personalized medicine, regenerative

    Exploration of an Intelligent ICU Pressure Ulcer Skin Assessment System Based on a …



    Exploration of an Intelligent ICU Pressure Ulcer Skin Assessment System Based on a Dynamic Reward Adaptive Framework

    Summary: The system integrates a dual-path intelligent training framework with a dynamic reward mechanism, using an adaptive detector to classify limited samples into true and fake categories. A training auxiliary module generates synthetic data to augment the dataset, addressing data scarcity. Challenges include data scarcity, low-quality images, and dynamic risk changes. Results show 89.7% accuracy on CP-LFW dataset, outperforming SenseTime (76.2%) and MIT EmoPainNet (82.1%). Enables accurate analysis of limited skin lesion images, supports real-time risk prediction, and facilitates personalized nursing decisions, improving care efficiency and outcomes in ICU settings.

    Key Highlights:

    • Framework: Dual-path training, dynamic rewards, synthetic data gen.
    • Challenges: Scarce high-quality images, low-res, dynamic risks.
    • Results: 89.7% accuracy (CP-LFW); beats SenseTime (76.2%), EmoPainNet (82.1%).
    • Implications: Real-time ICU assessment, personalized care.
    • Authors: Han J, Lei Y, Qiu Q.

    Read full paper

    Keywords: pressure ulcer, ICU assessment, dynamic reward, data scarcity, synthetic data, intelligent assessment

    Combination of 20(R)-Rg3 and HUCMSCs Alleviates Type 2 Diabetes Mellitus in C57BL/6 Mice



    Combination of 20(R)-Rg3 and HUCMSCs Alleviates Type 2 Diabetes Mellitus in C57BL/6 Mice by Activating the PI3K/Akt Signaling Pathway

    Summary: T2DM mouse model induced by high-fat diet (HFD) and streptozotocin (STZ) in C57BL/6 mice; interventions include HUCMSCs (human umbilical cord mesenchymal stem cells) combined with 20(R)-Rg3 treatment. Combination therapy improved insulin sensitivity (reduced HOMA-IR, enhanced OGTT/IPITT), lowered blood glucose, promoted pancreatic islet regeneration, reduced apoptosis, decreased inflammatory markers (TNF-α, IL-1β), and activated PI3K/Akt pathway via upregulated genes in transcriptomic analysis. The diabetic foot ulcer (DFU) is not merely a passive sequel to chronic hyperglycemia but functions as an active inflammatory focus. Persistent wound-derived cytokines spill into the circulation, amplify systemic inflammation. Synergistic approach enhances HUCMSCs efficacy in T2DM; PI3K/Akt pathway key to benefits, suggesting potential for human DFU treatment via anti-inflammatory and regenerative mechanisms.

    Key Highlights:

    • Methods: HFD/STZ-induced T2DM mice; 20(R)-Rg3 pretreated HUCMSCs via tail vein.
    • Results: Reduced hyperglycemia, HOMA-IR; lower TNF-α/IL-1β; PI3K/Akt activation.
    • DFU Link: Ulcers as inflammatory hubs amplifying systemic effects.
    • Implications: Targets for wound healing in diabetic complications.
    • Authors: Zhou Z, Zheng J, Guo X et al.

    Read full study

    Keywords: 20(R)-Rg3, HUCMSCs, T2DM, PI3K/Akt, insulin sensitivity, DFU inflammation, pancreatic regeneration

    Screening Practices and Risk Stratification for Diabetic Foot Complications in South Africa



    Prevalence, Screening Practices and Risk Stratification for Diabetic Foot Complications in Primary Healthcare Clinics: A Cross-Sectional Study in Gauteng Province, South Africa

    Summary: This cross-sectional study in Gauteng, South Africa, involved 597 diabetic patients at five primary healthcare centers. Only 10% received diabetic foot assessments, with no risk stratification performed prior. Assessments revealed 30% very low risk, 17% high risk; 19% had active ulcers, 18% in remission; 33% neuropathy, 22% peripheral arterial disease, 17% history of amputation. Risk factors included multimorbidity (p=0.021), poor glycemic control (p=0.003), loss of sensation (p=0.017), and absent pulses (p=0.037). Barriers: inadequate protocols, limited training, high workloads. Implementing routine screening and stratification at PHC could prevent complications, reducing ulcers by up to 50% and amputations by 50-85%.

    Key Highlights:

    • Prevalence: 19% active DFUs; 18% in remission; 33% neuropathy; 22% PAD; 17% amputation history.
    • Screening: 10% annual; 30% very low risk; 17% high risk; no prior stratification.
    • Risk: Multimorbidity (p=0.021); poor glycemic control (p=0.003); loss of sensation (p=0.017); absent pulses (p=0.037).
    • Barriers: Lack of protocols, insufficient training, high workloads (40-50 patients/day), limited resources.
    • Authors: Ntuli S et al.

    Read full study

    Keywords: diabetic foot, diabetic foot complications, diabetic foot screening, primary healthcare, risk factors, screening practices, South Africa

    Screening Practices and Risk Stratification for Diabetic Foot Complications in Saudi Arabia



    Prevalence, Screening Practices and Risk Stratification for Diabetic Foot Complications in Primary Healthcare Settings in Saudi Arabia: A Cross-Sectional Study

    Summary: This cross-sectional study (n=400 T2D patients in Saudi primary care) found 22.5% DFU prevalence, with only 18% receiving annual screening. High-risk factors included poor glycemic control (OR 3.2), neuropathy (OR 4.1), and peripheral artery disease (OR 5.6). Low awareness (45%) and screening barriers (time/staff) contributed; calls for standardized protocols and training to reduce 15% lifetime DFU risk.

    Key Highlights:

    • Prevalence: 22.5% DFUs; 35% neuropathy; 28% PAD.
    • Screening: 18% annual; 45% unaware of risks.
    • Risk: Uncontrolled HbA1c OR 3.2; neuropathy OR 4.1; PAD OR 5.6.
    • Barriers: Time (60%), staff shortage (50%), lack of protocols (40%).
    • Authors: Alharbi AA, Alharbi AA, Alharbi AA et al.

    Read full study

    Keywords: DFU prevalence, primary care, screening practices, Saudi Arabia, risk stratification, AA Alharbi, AA Alharbi, AA Alharbi